NetworkNewsBreaks – Daré Bioscience, Inc. (NASDAQ: DARE) Realizes $5.8M in Gross Proceeds Through Underwritten Public Offering
Daré Bioscience (NASDAQ: DARE) has closed an underwritten public offering of 5,261,250 of its common stock shares, including an additional 686,250 shares pursuant to the full exercise of the over-allotment option. The shares were sold, each at a public offering price of $1.10, resulting in approximately $5.8 million gross proceeds for Daré Bioscience, which it intends to use for working capital and general corporate purposes. ROTH Capital Partners acted as the sole book-running manager for the transaction. To view the full press release, visit http://nnw.fm/R1kzc About Daré Bioscience Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of…







